Marek P.
- Country
- Czechia
- Department
- N/A
Research Overview
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DT-101 in Adults with Major Depressive Disorder
- Efficacy and Safety of Psilocybin (COMP360) in Adults with Treatment-Resistant Depression: A Phase III Randomized, Double-Blind, Controlled Trial
- Long-term Safety Evaluation of Iclepertin in Schizophrenia Patients Post-Completion of Phase III Trials
Data & Insights
Has run more than one trial at 25 of 157 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the clinical management of tardive dyskinesia, focusing on innovative therapeutic approaches for patients with moderate to severe manifestations of the condition.
- Movement Disorders
- Long-term Maintenance Therapy
- Involuntary Movement Control
Their research extends to evaluating novel treatments for managing abnormal involuntary movements associated with tardive dyskinesia.
Psychiatric Disorders
The investigator conducts research in treatment-resistant depression, exploring novel therapeutic interventions combined with psychological support approaches.
- Depression Management
- Psychological Support Integration
- Treatment Resistance
Their work encompasses innovative approaches to improving depressive symptoms in adult patients.
Mental Health Research
The investigator focuses on schizophrenia treatment, particularly addressing cognitive impairment associated with the condition.
- Cognitive Function
- Long-term Safety Assessment
- Treatment Development
Their research includes evaluating novel therapeutic agents for managing cognitive symptoms in schizophrenia patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.